Immutep Limited (IMMP)
Stock Price:
$1.73 USD
-0.06 (-3.35%)
Updated Oct 30, 2020 2:55 PM EDT - Market open
Key Info
| Market Cap |
85.27M |
| Revenue (ttm) |
11.38M |
| Net Income (ttm) |
-9.29M |
| Shares Out |
49.29M |
| EPS (ttm) |
-0.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$1.73 |
| Previous Close |
$1.79 |
| Change ($) |
-0.06 |
| Change (%) |
-3.35% |
| Day's Open |
1.78 |
| Day's Range |
1.65 - 1.78 |
| Day's Volume |
90,635 |
| 52-Week Range |
0.53 - 3.10 |
More Stats
| Market Cap |
85.27M |
| Enterprise Value |
73.36M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.29M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.40 |
| FCF / Share |
-0.22 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
399,294 |
| Short Ratio |
0.85 |
| Short % of Float |
n/a |
| Beta |
1.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
7.49 |
| PB Ratio |
3.67 |
| Revenue |
11.38M |
| Operating Income |
-8.49M |
| Net Income |
-9.29M |
| Free Cash Flow |
-7.49M |
| Net Cash |
11.91M |
| Net Cash / Share |
0.24 |
| Gross Margin |
100.00% |
| Operating Margin |
-74.61% |
| Profit Margin |
-81.60% |
| FCF Margin |
-65.81% |
| ROA |
-21.62% |
| ROE |
-46.69% |
| ROIC |
-133.70% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.58*
(164.74% upside)
Low
4.28
Current: $1.73
High
5.00
Target: 4.58
*Average 12-month USD price target from 3 stock analysts.
Financial Performance
Financial numbers in millions AUD.
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 16.50 | 7.49 | 7.35 | 4.22 | 2.03 | 2.09 | 3.14 | 4.01 | 4.20 | 1.07 |
| Revenue Growth | 120.31% | 1.85% | 74.19% | 108.07% | -3.06% | -33.35% | -21.6% | -4.69% | 294.16% | - |
| Gross Profit | 16.50 | 7.49 | 7.35 | 4.22 | 2.03 | 2.09 | 3.14 | 4.01 | 4.20 | 1.07 |
| Operating Income | -12.31 | -17.35 | -11.69 | -9.35 | -61.47 | -13.93 | -13.33 | -15.11 | -17.27 | -14.13 |
| Net Income | -13.47 | -18.34 | -12.75 | -9.37 | -62.02 | -32.15 | -13.34 | -15.23 | -19.94 | -21.08 |
| Shares Outstanding | 339 | 303 | 208 | 61.85 | 52.54 | 36.86 | 31.98 | 31.98 | 31.98 | 31.98 |
| Earnings Per Share | -0.34 | -0.55 | -0.46 | -0.40 | -2.78 | -2.34 | -3.10 | -4.73 | -6.40 | -12.47 |
| Operating Cash Flow | -10.84 | -15.29 | -7.78 | -8.51 | -11.31 | -7.79 | -14.23 | -16.04 | -19.12 | -12.82 |
| Capital Expenditures | -0.02 | -0.04 | -0.01 | -0.01 | 0.10 | -0.05 | -0.10 | -0.51 | -0.57 | -0.04 |
| Free Cash Flow | -10.86 | -15.33 | -7.79 | -8.51 | -11.21 | -7.84 | -14.33 | -16.55 | -19.69 | -12.87 |
| Cash & Equivalents | 26.32 | 16.57 | 23.48 | 12.24 | 20.88 | 6.76 | 23.20 | 30.02 | 38.04 | 55.92 |
| Total Debt | 9.05 | 7.64 | 6.65 | 5.78 | 5.03 | 1.51 | - | - | - | - |
| Net Cash / Debt | 17.27 | 8.93 | 16.83 | 6.46 | 15.85 | 5.25 | 23.20 | 30.02 | 38.04 | 55.92 |
| Assets | 46.60 | 40.54 | 47.00 | 34.96 | 42.55 | 30.98 | 25.38 | 32.81 | 41.61 | 57.64 |
| Liabilities | 13.30 | 16.15 | 13.48 | 8.43 | 7.24 | 6.29 | 2.79 | 3.57 | 4.45 | 2.54 |
| Book Value | 33.30 | 24.39 | 33.52 | 26.53 | 35.32 | 24.69 | 22.59 | 29.25 | 37.16 | 55.10 |
Numbers in millions AUD, except per-share numbers.
Company Details
| Full Name |
Immutep Limited |
| CEO |
Marc Voigt |
Stock Information
| Ticker Symbol |
IMMP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMMP |
Description
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.